Lpath, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://lpath.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
- Conditions
- Healthy Subjects
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02341508
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01762033
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Florida Cancer Specialists, Inverness, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg EyleaDrug: 4.0 mg iSONEPDrug: 0.5 mg iSONEPDrug: sham injection
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT01414153
- Locations
- 🇺🇸
Retina Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retina Centers, P.C., Tucson, Arizona, United States
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
- Conditions
- Pigment Epithelial Detachment
- Interventions
- Drug: iSONEP (sonepcizumab/LT1009)
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01334255
- Locations
- 🇺🇸
Center For Retina & Macular Disease, Winter Haven, Florida, United States
🇺🇸Associates in Ophthalmology, West Mifflin, Pennsylvania, United States
🇺🇸Palmetto Retina Center, West Columbia, South Carolina, United States
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
- Conditions
- Neovascular Age Related Macular Degeneration
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00767949
- Locations
- 🇺🇸
Retinal Consultants of Arizona, LTD, Phoenix, Arizona, United States
🇺🇸Center for Retina and Macular Disease, Winter Haven, Florida, United States
🇺🇸Midwest Eye Institute, Indianapolis, Indiana, United States
- Prev
- 1
- 2
- Next